This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revision | ||
home:diseases:ankylosing_spondylitis [08.12.2019] – [Headline] sallieq | home:diseases:ankylosing_spondylitis [09.14.2022] (current) – external edit 127.0.0.1 | ||
---|---|---|---|
Line 58: | Line 58: | ||
CONCLUSION: The role of K. pneumoniae and anti-collagen antibodies in the aetiopathogenesis of CD and AS requires further study. | CONCLUSION: The role of K. pneumoniae and anti-collagen antibodies in the aetiopathogenesis of CD and AS requires further study. | ||
- | (({{pubmed> | + | (({{pmid> |
[[https:// | [[https:// | ||
===== Management ===== | ===== Management ===== | ||
- | The prevalence rate of hip involvement in AS patients varies from 10 to 23%, depending on the type of hip assessment. TNF-α blocking therapy significantly improved tender hip joints, and inflammatory US lesions including positive power Doppler. | + | The prevalence rate of hip involvement in AS patients varies from 10 to 23%, depending on the type of hip assessment. TNF-α blocking therapy significantly improved tender hip joints, and inflammatory US lesions including positive power Doppler. |
Line 69: | Line 69: | ||
Patients with ankylosing spondylitis (AS) warrant a comprehensive clinical assessment because of the lack of biomarkers of disease activity, prognosis and response to biologic therapy. Multiple AS-related questionnaires have been developed to assess the disease status accurately, but feasibility remains a problem in clinical practice. | Patients with ankylosing spondylitis (AS) warrant a comprehensive clinical assessment because of the lack of biomarkers of disease activity, prognosis and response to biologic therapy. Multiple AS-related questionnaires have been developed to assess the disease status accurately, but feasibility remains a problem in clinical practice. | ||
- | The Bath Ankylosing Disease Activity Index remains the gold standard for assessing disease activity in a routine practice, despite poor correlation with C-reactive protein (CRP) levels and MRI inflammation. | + | The Bath Ankylosing Disease Activity Index remains the gold standard for assessing disease activity in a routine practice, despite poor correlation with C-reactive protein (CRP) levels and MRI inflammation. |
- | ==== D-free calcium ==== | ||
- | < | ||
- | |||
- | I do fair better with fortified calcium foods than I do calcium supplements! | ||
==== TNF inhibitor dose ==== | ==== TNF inhibitor dose ==== | ||
- | In patients with ankylosing spondylitis in clinical remission for at least 6 months, dose reduction is non-inferior to full TNF inhibitor doses to maintain LDA after 1 year. Serious adverse events may be less frequent with reduced doses. | + | In patients with ankylosing spondylitis in clinical remission for at least 6 months, dose reduction is non-inferior to full TNF inhibitor doses to maintain LDA after 1 year. Serious adverse events may be less frequent with reduced doses. |
Line 87: | Line 83: | ||
< | < | ||
+ | |||
+ | ==== D-free calcium ==== | ||
+ | |||
+ | < | ||
+ | |||
+ | I do fair better with fortified calcium foods than I do calcium supplements! | ||
==== Related research on osteonecrosis ==== | ==== Related research on osteonecrosis ==== | ||
- | The findings from this study indicated that even short-term oral use of alendronate led to ONJ in a subset of patients after certain dental procedures were performed. These findings have important therapeutic and preventive implications. | + | The findings from this study indicated that even short-term oral use of alendronate led to ONJ in a subset of patients after certain dental procedures were performed. These findings have important therapeutic and preventive implications. |
- | Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw (({{pubmed> | + | Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw (({{pmid> |
{{tag> | {{tag> | ||
+ | < | ||
===== Notes and comments ===== | ===== Notes and comments ===== | ||
Line 115: | Line 118: | ||
< | < | ||
- | Time to prove the infective etiology of ankylosing spondylitis and related spondylarthritides: | + | Time to prove the infective etiology of ankylosing spondylitis and related spondylarthritides: |
Zeidler H, Rihl M. | Zeidler H, Rihl M. | ||
Line 153: | Line 156: | ||
</ | </ | ||
- | ===== References ===== | + | ===== References =====</ |